Monitoring the safe use of clozapine: A consensus view from Victoria, Australia

Michael Berk, Joanna Fitzsimons, Timothy Lambert, Christos Pantelis, Jayashri Kulkarni, David Jonathan Castle, Elizabeth W Ryan, Sean Jespersen, Patrick D McGorry, Gregor E Berger, Bill Kuluris, Tom Callaly, Seetal Dodd

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)

Abstract

Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patients with clozapine are currently required to register their patients on a centrally administered data network and to conform to strict protocols. The consensus statement documented in this article extends existing protocols by recommending monitoring of patients treated with clozapine for additional adverse effects during treatment. This consensus statement reflects the current practice at five major public psychiatric hospitals in Victoria, Australia, for the monitoring and management of clozapine-related adverse events, and has been implemented at these sites because of emerging safety concerns associating clozapine with cardiovascular and metabolic adverse effects.
Original languageEnglish
Pages (from-to)117 - 127
Number of pages11
JournalCNS Drugs
Volume21
Issue number2
Publication statusPublished - 2007

Cite this